HK1039477A1 - 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors - Google Patents
2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptorsInfo
- Publication number
- HK1039477A1 HK1039477A1 HK01108745A HK01108745A HK1039477A1 HK 1039477 A1 HK1039477 A1 HK 1039477A1 HK 01108745 A HK01108745 A HK 01108745A HK 01108745 A HK01108745 A HK 01108745A HK 1039477 A1 HK1039477 A1 HK 1039477A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- rxr
- retinoid
- receptors
- acid derivatives
- selective activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
- C07C57/50—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
- C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/164,950 US6147224A (en) | 1998-10-01 | 1998-10-01 | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
PCT/US1999/021712 WO2000020370A1 (en) | 1998-10-01 | 1999-09-20 | 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1039477A1 true HK1039477A1 (en) | 2002-04-26 |
Family
ID=22596791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01108745A HK1039477A1 (en) | 1998-10-01 | 2002-02-25 | 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
Country Status (17)
Country | Link |
---|---|
US (1) | US6147224A (zh) |
EP (2) | EP1388534A3 (zh) |
JP (1) | JP2002526516A (zh) |
KR (2) | KR20010075457A (zh) |
CN (1) | CN1328538A (zh) |
AR (1) | AR020691A1 (zh) |
AT (1) | ATE254593T1 (zh) |
AU (1) | AU757932B2 (zh) |
BR (1) | BR9914256A (zh) |
CA (1) | CA2346034A1 (zh) |
DE (1) | DE69912973T2 (zh) |
ES (1) | ES2207339T3 (zh) |
HK (1) | HK1039477A1 (zh) |
NZ (1) | NZ510528A (zh) |
TW (1) | TW580494B (zh) |
WO (1) | WO2000020370A1 (zh) |
ZA (1) | ZA200102635B (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
WO2001016133A2 (en) | 1999-08-27 | 2001-03-08 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators |
TR200200507T2 (tr) | 1999-08-27 | 2002-10-21 | Ligand Pharmaceuticals Inc | Androjen reseptörü modülatör bileşikleri ve metotları |
WO2001019770A2 (en) | 1999-09-14 | 2001-03-22 | Ligand Pharmaceuticals Incorporated | Rxr modulators with improved pharmacologic profile |
US6906046B2 (en) | 2000-12-22 | 2005-06-14 | Celltech R & D Inc. | Pharmaceutical uses and synthesis of benzobicyclooctanes |
US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
EP1408946A4 (en) * | 2001-03-27 | 2004-06-09 | Circagen Pharmaceutical | HISTONE DEACETYLASE INHIBITORS |
US8026280B2 (en) | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
US6495719B2 (en) | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US6388105B1 (en) * | 2001-09-27 | 2002-05-14 | Allergan Sales, Inc. | Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
US6720423B2 (en) | 2002-04-30 | 2004-04-13 | Allergan, Inc. | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
CA2486303C (en) | 2002-05-22 | 2013-04-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors based on alpha-ketoepoxide compounds |
CA2506504A1 (en) | 2002-11-20 | 2004-06-03 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
US6683092B1 (en) | 2003-04-09 | 2004-01-27 | Allergan, Inc. | [3-(c5-14alkyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-phenyl and [3-(c5-14alkyl-2-oxo-1,2,3,4- tetrahydro-quinolin-6-yl)-3-oxo-propenyl]-heteroaryl derivatives having anti-tumor activity |
US6734193B1 (en) | 2003-06-03 | 2004-05-11 | Allergan, Inc. | (1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity |
US6936636B2 (en) * | 2003-06-26 | 2005-08-30 | Allergan, Inc. | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity |
US6887896B1 (en) | 2003-10-29 | 2005-05-03 | Allergan, Inc. | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity |
SI1937244T1 (sl) | 2005-09-30 | 2018-12-31 | Io Therapeutics, Llc | Zdravljenje raka s specifičnimi RXR agonisti |
US20070185055A1 (en) * | 2006-02-06 | 2007-08-09 | Guang Liang Jiang | Method for treating cachexia with retinoid ligands |
CN110151745A (zh) | 2011-12-13 | 2019-08-23 | Io治疗公司 | 使用rxr激动剂的自身免疫紊乱的治疗 |
KR102225715B1 (ko) * | 2013-07-09 | 2021-03-09 | 토소가부시키가이샤 | 아다만틸기를 가진 환상 아진 화합물, 제조 방법, 및 상기 화합물을 구성 성분으로서 함유하는 유기 전계발광소자 |
AU2016344018B2 (en) | 2015-10-31 | 2019-02-28 | Io Therapeutics, Inc. | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones |
US10835507B2 (en) | 2016-03-10 | 2020-11-17 | Io Therapeutics, Inc. | Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones |
CN115227826A (zh) | 2016-03-10 | 2022-10-25 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
WO2019060600A1 (en) | 2017-09-20 | 2019-03-28 | Io Therapeutics, Inc. | TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS |
JP2021503464A (ja) * | 2017-11-17 | 2021-02-12 | アイオー セラピューティクス インコーポレイテッド | レチノイドx受容体特異的なレチノイドの調製のための化合物および合成方法 |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
WO2023108012A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
AU2022407454A1 (en) | 2021-12-07 | 2024-06-06 | Board Of Regents, The University Of Texas System | Use of an rxr agonist in treating drug resistant her2+ cancers |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8826760D0 (en) * | 1988-11-16 | 1988-12-21 | Wellcome Found | Pesticides |
ES2066750T3 (es) * | 1991-12-18 | 1998-07-01 | Salk Inst For Biological Studi | Metodo para la modulacion de procesos mediatizados por receptores de retinoides y compuestos de utilidad en dicho metodo. |
EP0983992B1 (en) * | 1992-04-22 | 2005-10-26 | Ligand Pharmaceuticals Incorporated | Compounds having selectivity for retinoid x receptors |
JPH08511027A (ja) * | 1993-01-11 | 1996-11-19 | リガンド・ファーマシューティカルズ・インコーポレーテッド | レチノイドxレセプターに対して選択的な活性を有する化合物、およびレチノイドxレセプターによって媒体されたプロセスの調節手段 |
US5455265A (en) * | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
KR100363545B1 (ko) * | 1994-08-10 | 2003-02-19 | 에프. 호프만-라 로슈 아게 | 레틴산x-수용체리간드 |
IL116259A (en) * | 1994-12-19 | 2000-07-16 | American Cyanamid Co | Analogs of 9-cis retinoic acid and their use |
US5648514A (en) * | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
US5543534A (en) * | 1994-12-29 | 1996-08-06 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity |
US5675033A (en) * | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5776699A (en) * | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
EP1336600A3 (en) * | 1995-10-06 | 2004-07-07 | Ligand Pharmaceuticals Incorporated | Dimer-selective RXR modulators and methods for their use |
US5723666A (en) * | 1996-06-21 | 1998-03-03 | Allergan | Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5728846A (en) * | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
EP1161410B1 (en) * | 1999-03-08 | 2004-05-12 | Basilea Pharmaceutica AG | Retinoid antagonists and use thereof |
-
1998
- 1998-10-01 US US09/164,950 patent/US6147224A/en not_active Expired - Fee Related
-
1999
- 1999-09-20 EP EP03025774A patent/EP1388534A3/en not_active Withdrawn
- 1999-09-20 AT AT99970078T patent/ATE254593T1/de not_active IP Right Cessation
- 1999-09-20 CN CN99813787A patent/CN1328538A/zh active Pending
- 1999-09-20 DE DE69912973T patent/DE69912973T2/de not_active Expired - Fee Related
- 1999-09-20 AU AU60513/99A patent/AU757932B2/en not_active Ceased
- 1999-09-20 CA CA002346034A patent/CA2346034A1/en not_active Abandoned
- 1999-09-20 BR BR9914256-2A patent/BR9914256A/pt not_active Application Discontinuation
- 1999-09-20 WO PCT/US1999/021712 patent/WO2000020370A1/en active IP Right Grant
- 1999-09-20 NZ NZ510528A patent/NZ510528A/xx unknown
- 1999-09-20 EP EP99970078A patent/EP1117628B1/en not_active Expired - Lifetime
- 1999-09-20 JP JP2000574489A patent/JP2002526516A/ja active Pending
- 1999-09-20 ES ES99970078T patent/ES2207339T3/es not_active Expired - Lifetime
- 1999-09-20 KR KR1020017004018A patent/KR20010075457A/ko active IP Right Grant
- 1999-10-01 AR ARP990104996A patent/AR020691A1/es not_active Application Discontinuation
- 1999-10-12 TW TW088116960A patent/TW580494B/zh not_active IP Right Cessation
-
2001
- 2001-03-30 ZA ZA200102635A patent/ZA200102635B/en unknown
-
2002
- 2002-02-25 HK HK01108745A patent/HK1039477A1/xx not_active IP Right Cessation
-
2006
- 2006-09-20 KR KR1020060091029A patent/KR20060118367A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2346034A1 (en) | 2000-04-13 |
US6147224A (en) | 2000-11-14 |
BR9914256A (pt) | 2001-07-03 |
EP1388534A2 (en) | 2004-02-11 |
TW580494B (en) | 2004-03-21 |
CN1328538A (zh) | 2001-12-26 |
EP1388534A3 (en) | 2004-02-25 |
AR020691A1 (es) | 2002-05-22 |
DE69912973T2 (de) | 2004-07-22 |
EP1117628A1 (en) | 2001-07-25 |
AU757932B2 (en) | 2003-03-13 |
EP1117628B1 (en) | 2003-11-19 |
WO2000020370A1 (en) | 2000-04-13 |
KR20060118367A (ko) | 2006-11-23 |
ES2207339T3 (es) | 2004-05-16 |
AU6051399A (en) | 2000-04-26 |
KR20010075457A (ko) | 2001-08-09 |
JP2002526516A (ja) | 2002-08-20 |
ZA200102635B (en) | 2002-10-18 |
DE69912973D1 (de) | 2003-12-24 |
NZ510528A (en) | 2003-04-29 |
ATE254593T1 (de) | 2003-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1039477A1 (en) | 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors | |
IL139636A0 (en) | New 3-aryl-2-hydroxypropionic acid derivative (i) | |
HUP0001322A3 (en) | Sulphinic acid derivatives, method for producing them, and their use | |
PT925298E (pt) | Derivados 6,6-hetero-biciclicos substituidos | |
AP9701052A0 (en) | Substituted pyrido- or pyrimido- containing 6,6- or 6,77-bicyclic derivatives | |
NL1012963A1 (nl) | 2-Amino-bicyclo (3.1.0)hexaan-2,6 dicarbonzuur derivaten en een werkwijze voor de bereiding ervan. | |
PL323780A1 (en) | Substituted compounds: (sulphinic, sulphonic, sylphonylaamino sulphinylamino) n-[(aminoiminomethyl)-phenylalkyl]-azaheterocyclic amides | |
FR2767524B1 (fr) | Procede ameliore d'obtention de paraxylene a partir de coupes de c8 aromatiques | |
EP0951283A4 (en) | NEW METABOLITE OF ARACHIDONIC ACID: 4 PM | |
HUP0103659A2 (en) | Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives | |
BR9502431A (pt) | Método para minimizar o intervalo de tempo para um receptor operando durante um modo de recepçao descontinua | |
HU9502684D0 (en) | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkane-carboxylic acid derivatives | |
AU2001243630A1 (en) | 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr)receptors | |
EP0845457A4 (en) | 2,2-DIDEUTERO-5-AMINOLEVULINIC ACID | |
ID28539A (id) | Imidazo (1,2a) azina bersubstitusi sebagai penghambat selektif cox-2 | |
AU2003230720A1 (en) | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentaidenoic acid derivatives having selective activity for retinoid x (rxr) receptors | |
HK1039620A1 (en) | High purity compound (7alpha, 17alpha)-17-hydroxyl-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one | |
GB2329656B (en) | A sinker bar for cable-operated well apparatus | |
FI973644A0 (fi) | Uusi menetelmä 2,3-dihydrobentsofuranolijohdannaisten valmistamiseksi | |
AU3770600A (en) | Selective retinoic acid analogs | |
AU2002331876A1 (en) | Benzofuran, indole or benzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors | |
HU9203078D0 (en) | Method for regionally selective production of 1,5-diamide-pyrazole derivatives | |
ZA957615B (en) | Process for R(+)1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenyl-3-cyclohexen-1-yl) methyl]pyridine a central nervous system agent | |
AU6864100A (en) | Method for producing 2,6-dimethylnaphthalene | |
HU9801312D0 (en) | Process for producing 3,3-dimethyl-butyric acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20090920 |